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The regulation of B cell life span is essential for 
normal immunity. The short life of newly gen-
erated immature B cells assures their rapid turn-
over and permits selection of nonautoreactive 
and functionally fi  t mature B cells. The  longevity 
of mature B cells is required to maintain a highly 
diverse immunoglobulin repertoire in  preparation 
for antigenic challenge. The exceeded life span 
of antigen-experienced memory cells assures the 
most effi   cient immune response to recurring 
pathogens (1, 2).
The survival of B cells is sustained by a con-
stant and apparently ligand-independent tonic 
signal mediated by the cell surface–expressed B 
cell antigen receptor (BCR) (3, 4). In addition, 
survival of B cells is supported by B cell–activating 
factor of the TNF family (BAFF; also known as 
BLyS) produced by stromal cells and various cell 
types of myeloid origin. BAFF promotes B cell 
survival by a triggering of the B cell surface–
  expressed BAFF receptor (BAFF-R) (5, 6).
Both BCR and BAFF-R signals are crucial 
for B cell survival. Genetic ablation of the BCR 
from mature B cells leads to B cell death (3, 4). 
Similarly, inactivating mutations in BAFF or 
BAFF-R or BAFF neutralization by a geneti-
cally engineered soluble BAFF-binding protein 
reduce B cell life span and lead to immuno-
defi  ciency (7–12). Conversely, increased levels 
of BAFF in the serum of mice that express both 
endogenous and transgenic BAFF extend B cell 
survival beyond physiological limits (13, 14), 
but the negative eff  ect of this prolonged B cell 
life span causes BAFF-transgenic mice to de-
velop lupus-like autoimmune disease.
The signaling mechanisms of BAFF-medi-
ated B cell survival are not very well under-
stood. It is known that binding of BAFF to 
BAFF-R causes processing of NF-κB2 precur-
sor protein p100 to active p52, which has the 
potential to initiate transcription of antiapop-
totic genes such as members of the Bcl-2 family 
(15, 16). BAFF also counteracts BCR-induced 
up-regulation of Bim in an Erk-dependent 
fashion (17). Furthermore, BAFF promotes 
the cytoplasmic retention of protein kinase C δ 
(PKCδ), thus containing the proapoptotic po-
tential of PKCδ upon translocation to the nu-
cleus (18). However, it is not clear whether this 
eff  ect refl  ects a direct impact of BAFF on PKCδ 
or the overall physiological condition of BAFF-
treated B cells.
It is well established that the bioenergetic 
state of cytokine-treated hematopoietic cells 
and T lymphocytes correlates directly with their 
survival (for review see reference 19). Prosur-
vival cytokines such as IL-3 and IL-7 promote 
nutrient uptake, increase glycolysis rates, and 
regulate mitochondrial energy homeostasis (20, 
21). Therefore, it seems plausible that, similar 
to other prosurvival cytokines, BAFF also con-
trols B cell survival by the regulation of B cell 
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metabolic fi  tness. In this paper, we identify PKCβ and Akt as 
critical components of a BAFF-induced signaling chain that 
controls B cell survival and metabolic fi  tness.
RESULTS
BAFF promotes B cell metabolic fi  tness and prepares 
for antigen-induced proliferation
Incubation of mature B cells with BAFF drastically changes 
the state of B cell metabolism. Treatment with BAFF increases 
B cell size, cellular protein content, and mitochondrial mem-
brane potential (Fig. 1, A–C). BAFF-treated cells show changes 
in gene transcription that direct these cells toward production 
of proteins required for glycolytic metabolism and cell cycle 
progression. Analysis of polyribosome-associated and, hence, 
actively translated mRNAs revealed two large mRNA clusters 
that were particularly prominent in BAFF-treated B cells 
(Fig. 2, A–C; and Table S1, available at http://www.jem.org/
cgi/content/full/jem.20060990/DC1). The fi  rst cluster contains 
mRNAs collectively related to glycolysis. The second cluster 
overrepresented in BAFF-stimulated B cells contains mRNAs 
for proteins controlling cell cycle, chromosome condensation, 
and mitosis. The BAFF-induced up-regulation of cell cycle pro-
gression proteins such as cyclin D and cyclin E, Cdk4, Mcm2 
and 3, the proliferation marker Ki67, and Survivin was inde-
pendently confi  rmed by protein expression analysis (Fig. 3 A). 
Analysis of total RNA from BAFF-treated cells showed that 
the abundance of these transcripts refl  ects overall changes in 
the pattern of gene expression rather then BAFF-mediated 
  recruitment of the selected mRNAs into polyribosomes 
(Table S2).
Stimulation with BAFF resulted not only in the tran-
scription and translation of genes required for cell cycle pro-
gression but also in phosphorylation of the key cell cycle 
controlling Rb protein (Fig. 3 A, bottom), which is prereq-
uisite for the release of E2F and cell cycle entry into S phase 
(22). Despite the substantial accumulation and modifi  cation 
of cell cycle–controlling proteins, BAFF does not induce B 
cell proliferation in vitro (Fig. 3 B). However, preincuba-
tion of B cells with BAFF accelerates proliferation in response 
to BCR stimulation compared with BCR-only triggered 
cells (Fig. 3 B). This result points to a role of BAFF in main-
taining B cells in a state of immediate responsiveness to 
  antigenic stimulation.
BAFF activates Akt and induces phosphorylation of key 
regulatory Akt targets
Increased protein synthesis in response to BAFF suggests 
that BAFF controls activation of proteins required for trans-
lation. Indeed, treatment with BAFF caused phosphoryla-
tion of eukaryotic translation initiation factor 4E (eIF4E) 
and its inhibitor, eIF4E-binding protein 1 (4E-BP1; Fig. 4 A). 
Both are required for active protein synthesis: phosphory-
lation of eIF4E increases its binding to capped mRNAs, 
whereas 4E-BP phosphorylation disrupts its binding to 
eIF4E. Treat  ment with BAFF also leads to phosphorylation 
of S6 ribosomal protein, a hallmark of active protein syn-
thesis (23–25).
Phosphorylation of 4E-BP, which is known to be con-
trolled by Akt and Pim-2 (19), suggested an involvement 
of these kinases in BAFF signaling. Activation of Akt re-
quires its recruitment to the plasma membrane, where it 
binds to the lipid second messenger phosphatidyl inositol-
3,4,5-triphosphate via its pleckstrin homology domain. 
This induces a conformational change, which allows for 
Akt phosphorylation at threonine 308 by PDK1 and at ser-
ine 473 by a second kinase, whose identity is still contro-
versial (26, 27).
We found that treatment with BAFF led to a rapid phos-
phorylation of Akt at both S473 and T308, which, after a 
transitory decline after 1 h of stimulation, regained a stably 
high level by 24 h and beyond (Fig. 4 B and not depicted). 
Activation of Akt by BAFF was associated with the phos-
phorylation of several Akt targets known to control cell sur-
vival and metabolism (Fig. 4 C). First, treatment with BAFF 
lead to phosphorylation of the GTPase-activating protein 
tuberous sclerosis complex 2 (TSC2), which promotes pro-
tein synthesis through activation of mammalian target of 
Figure 1.  BAFF increases size, protein content, and mitochondrial 
membrane potential of B cells. Data represent three independent experi-
ments. (A) Mature B cells were incubated in culture medium in the presence 
of BAFF, and the cell size was measured by FACS analysis of the forward 
scatter (FSC). (B) Protein amount per million B cells. Error bars in A 
and B represent SD. (C) Mitochondrial membrane potential was meas-
ured by TMRE labeling. Histograms show the TMRE fluorescence of 
B cells incubated in the absence (shaded area, continuous line) or presence 
(open area, bold line) of BAFF. In control samples (dashed lines), membrane 
potential was dissipated by addition of the uncoupling agent carbonyl 
  cyanide m-chlorophenyl hydrazone.JEM VOL. 203, October 30, 2006  2553
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  rapamycin (28, 29). Second, BAFF induced the phosphory-
lation and, hence, inactivation of glycogen synthase kinase–3 
(GSK-3). GSK-3 has been found to cause apoptosis by 
  inducing MCL1 degradation and compromising mitochon-
drial membrane integrity (30). Finally, stimulation of B cells 
with BAFF led to phosphorylation of FoxO1 and its subse-
quent degradation. Members of the FoxO family of transcrip-
tion factors are known to play a key role in the regulation of 
genes required for cell cycle progression, glycolytic metabo-
lism, and survival (31, 32).
Growth factor stimulation of hematopoietic cells in-
duces Pim-2 expression, which confers resistance to atro-
phy and cell death (33). Treatment with BAFF strongly 
induced all three isoforms of Pim-2 within 24 h of stimula-
tion (Fig. 4 D).
BAFF-induced Akt activation depends on phosphoinositide 
3-kinase (PI3K) activity
Akt-activation requires its binding to specifi  c phosphoinosi-
tides, which are generated by PI3K at the plasma membrane 
(27). The predominant form of PI3K in B cells consists of 
the regulatory subunit p85α and the catalytic subunit p110δ 
(34). We found that treatment with BAFF led to tyrosine 
phosphorylation of a p85-associated protein with a molecular 
weight of approximately p110 (Fig. 5 A). Sequence analysis 
of a protein that co-migrated with phospho-p110 confi  rmed 
that this protein represents the catalytic subunit p110δ 
  (unpublished data). It is therefore possible that BAFF   activates 
PI3K by inducing the tyrosine phosphorylation of its catalytic 
subunit. A similar phenomenon has previously been reported 
in B cell lines stimulated through the BCR (35, 36).
Figure 2.  BAFF induces selective changes in gene transcription. The 
expression pattern and levels of polysome-associated mRNAs in unstimu-
lated and BAFF-treated B cells were determined by Affymetrix microarray 
analysis (Table S2). The biological signifi  cance of BAFF-induced changes in 
gene expression was then analyzed using the GO tool GoMiner. GO catego-
ries representing biological processes are displayed as a directed acyclic 
graph, and those overrepresented in BAFF-stimulated cells are marked. 
(A) Colors indicate a statistical signifi  cance of P < 0.001 (pink) or P < 0.0001 
(red). (B and C) Two prominent clusters of overrepresented GO categories are 
framed and displayed as 1 glycolysis and 2 cell cycle. Labeling represents GO 
“Biological Process” category names. Colors denote p-values as in A. Gene 
identities for the displayed GO categories are listed in Table S1.2554  BAFF MEDIATES B CELL SURVIVAL AND GROWTH VIA AKT ACTIVATION | Patke et al.
The activation of PI3K by BAFF is important for the regu-
lation of Akt activation and B cell survival. Treatment of 
B cells with the PI3K-specifi  c inhibitor LY294002 diminished 
BAFF-induced activation of Akt and phosphorylation of Akt 
target proteins (Fig. 5 B and Fig. S1, available at http://www.
jem.org/cgi/content/full/jem.20060990/DC1). Consistently, 
BAFF-mediated B cell survival was severely impaired by con-
centrations of LY294002, which abolish Akt activity (Fig. 5 C). 
The half-life of the phosphoinositide products of PI3K is lim-
ited by the lipid phosphatase and tensin homologue deleted on 
chromosome 10 (PTEN), but BAFF did not appear to aff  ect 
PTEN activity (Fig. S2), as judged by phosphorylation of the 
inhibitory PTEN phosphorylation site serine 380 (37).
PKC𝗃 controls BAFF-mediated activation of Akt
Akt activation requires two sequential events. Initially, Akt 
binding to the phosphoinositide products of PI3K induces 
a conformational change in the protein. This allows for its 
phosphorylation at two essential sites: T308 in the activation 
loop is phosphorylated by PDK1, whereas the identity of the 
kinase that phosphorylates the C-terminal S473 residue 
  remains to be determined (26, 27). In search of the kinase, 
which is responsible for Akt S473 phosphorylation and B cell 
survival in response to BAFF, we tested the role of PKCβ in 
BAFF-mediated signaling. This choice was based on two ma-
jor reasons. First, coincubation with recombinant PKCβ leads 
to Akt phosphorylation at S473 but not T308 (38). Second, 
PKCβ defi  ciency in mice causes a decline in B cell survival 
in vitro and in vivo (39, 40).
We initially assessed the ability of BAFF to activate PKCβ 
by analysis of BAFF-induced PKCβ translocation to the plasma 
membrane. This translocation is an activation hallmark for 
phospholipid-dependent classic PKCs, including PKCβ (41–
43), and triggering of B cells through the BCR leads to trans-
location of PKCβ into specialized membrane microdomains 
called lipid rafts (44). We found that treatment of B cells with 
BAFF increased the amount of membrane-associated PKCβ 
(Fig. 6 A). A similar level of BAFF-induced membrane translo-
cation was observed for Akt (Fig. 6 A). Notably, membrane 
translocation of PKCβ in response to BAFF occurred outside 
lipid rafts (Fig. S3, available at http://www.jem.org/cgi/con-
tent/full/jem.20060990/DC1). Because lipid rafts of BAFF-
triggered B cells did also not contain Akt or PDK1, we conclude 
that BAFF-induced Akt activation is a raft-independent event.
Figure 3.  BAFF induces up-regulation of cell cycle–controlling pro-
teins but not entry into S phase. (A) Purifi  ed B cells were incubated with 
BAFF for the indicated times, and the expression levels of cell cycle regulatory 
proteins cyclin D2, cyclin E, Cdk4, Mcm2, Mcm3, Ki67, Survivin, and Rb were 
measured by Western blotting. Protein loading was controlled by tubulin 
expression level analysis. Numbers represent the fold induction normalized to 
the Tubulin signal. Hyperphosphorylated Rb (pRb) is identifi  ed by a migratory 
shift. (B) B cell proliferation in vitro was measured by BrdU incorporation. 
Frequencies of BrdU+ B cells incubated in medium alone (diamonds); in the 
presence of BAFF (closed triangles), anti-IgM (closed squares), or BAFF and 
anti-IgM (open triangles); or after preincubation with BAFF for 24h followed 
by anti-IgM treatment for the indicated times (open squares) are shown.JEM VOL. 203, October 30, 2006  2555
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In addition to PKCβ translocation to the plasma mem-
brane, BAFF promotes the association of PKCβ with Akt 
(Fig. 6 B). This association does not depend on PI3K activity 
(Fig. S4, available at http://www.jem.org/cgi/content/full/
jem.20060990/DC1), but it is functionally important, as 
BAFF-induced Akt phosphorylation at S473 was greatly re-
duced in PKCβ-defi  cient B cells (Fig. 6 C). In contrast, Akt 
phosphorylation at the PDK1 target site T308 was similar 
between wild-type and mutant cells. The functional link be-
tween PKCβ and Akt is specifi  c to BAFF signaling, as stimu-
lation through the BCR induced Akt phosphorylation in 
PKCβ-defi  cient B cells at wild-type levels (Fig. 6 D).
Loss of PKC𝗃 has an impact on BAFF-mediated 
cellular responses
PKCβ-defi  cient B cells exhibit poor survival in vitro in the 
absence of stimuli (Fig. 7 A) (40). Treatment with BAFF pro-
motes the viability of mutant B cells, although they fail to 
reach wild-type survival levels regardless of the BAFF dose 
and the duration of treatment. Although PKCβ-defi  cient cells 
were partially responsive to the survival action of BAFF, its 
ability to support B cell growth in vitro was severed by lack 
of PKCβ (Fig. 7, A and B). These results suggest that the 
PKCβ-mediated Akt signaling element contributes mostly to 
BAFF-mediated B cell fi  tness rather than mere survival. Altered 
Figure 4.  BAFF activates proteins required for protein translation 
and cell survival. (A) Purifi  ed B cells were incubated with BAFF for the indi-
cated times, and phosphorylation of proteins that control translation was 
measured by Western blot analysis of eIF4E (pS209), 4E-BP1 (pS65), and S6 
(pS235/236). Membranes were stripped and reprobed with nonphospho-
specifi  c antibodies against the respective proteins. Numbers represent the fold 
change of the phosphospecifi  c signal normalized to the nonphosphospecifi  c 
signal. (B) BAFF-induced Akt phosphorylation on S473 and T308 was meas-
ured by immunoblot analysis using the respective phosphospecifi  c antibody 
(top). Akt expression was controlled by reprobing with a nonphosphospecifi  c 
Akt antibody. Quantifi  cation was done as in A. (C) BAFF-induced phosphor-
ylation of TSC2 at T1462 and of FoxO1 at S256 were measured by sequential 
immunoblot analysis (left). Erk is provided as a loading control to illustrate 
changes in FoxO1 total protein content. BAFF-induced phosphorylation of 
GSK-3β at S9 was measured in a similar fashion on a separate gel (right). 
In all cases, the amount of tested proteins was measured by reprobing the 
immunoblots with nonphosphospecifi  c antibodies against the respective 
pro teins.  Quantifi  cation was done as in A. (D) BAFF induces expression of 
Pim-2. The positions of three different Pim-2 isoforms are indicated. Erk expre-
ssion is provided as a protein loading control in C and D. n.s., nonspecifi  c.2556  BAFF MEDIATES B CELL SURVIVAL AND GROWTH VIA AKT ACTIVATION | Patke et al.
cellular responses of PKCβ-defi  cient B cells were not caused 
by defective surface expression of BAFF-R (Fig. 7 C), argu-
ing for a cell-intrinsic BAFF signaling defect in the absence 
of PKCβ.
The involvement of PKCβ in BAFF-mediated signaling 
is indirectly supported by the pattern of changes in the 
PKCβ-defi  cient, peripheral B cell compartment. In the ab-
sence of BAFF signaling, B cell maturation arrests between 
the T1 (CD21lo) and the T2 (CD21hi) stages (7, 10–12). 
PKCβ defi  ciency impairs B cell maturation in a fashion simi-
lar to failed BAFF signaling, albeit at a lower magnitude. In 
addition, the size of the peripheral PKCβ-defi  cient B cell 
compartment falls to  70% of wild-type levels (39), and im-
mature B cells prevail over mature B cells in the spleen of 
mutant mice, as judged by surface IgM and IgD expression 
(Fig. 7 D). Collectively, these observations suggest a partial 
defect in BAFF-mediated signaling and peripheral B cell mat-
uration in the absence of PKCβ.
PKC𝗃 does not control BAFF-induced regulation 
of NF-𝗋B and PKC𝗅
BAFF’s prosurvival function has been linked to its ability to 
  activate the processing of the NF-κB2 protein p100 into the 
transcriptionally active form p52 (15, 16). We fi  nd that BAFF-
induced p100-p52 processing was not aff  ected by the absence of 
PKCβ (Fig. 8 A). We have previously shown that BAFF controls 
B cell survival through cytoplasmic retention of the proapop-
totic kinase PKCδ (18). However, the ratio of cytoplasmic versus 
nuclear PKCδ was not altered by PKCβ defi  ciency (Fig. 8 B). 
We conclude that the BAFF-mediated regulation of NF-κB 
and PKCδ occurs independent of PKCβ.
D  I  S  C  U  S  S  I  O  N 
Our fi  ndings show that like cytokines such as IL-3 and IL- 7, 
which promote survival of hematopoietic cells, BAFF sup-
ports B cell survival by increasing metabolic fi  tness. Treat-
ment of B cells with BAFF induces transcription of mRNAs 
that encode components of carbohydrate metabolism. The 
BAFF-induced metabolic bias toward glycolysis might be es-
pecially important for B cell survival in lymphoid organs and 
at infl  ammatory sites where oxygen tension is low compared 
with arterial blood (45, 46). In this environment, activation 
of glycolysis will provide energy to sustain the active protein 
synthesis and cell growth caused by BAFF. Indeed, prolonged 
BAFF treatment led to expression of the hypoxia-inducible 
factor α (unpublished data).
Normally, accumulation of proteins, particular those con-
trolling cell cycle, and increase in cell volume precedes cell 
Figure 5.  PI3K controls BAFF-induced Akt activation and B cell 
survival. (A) BAFF induces phosphorylation of p110. The PI3K subunit 
p85 was immunoprecipitated from extracts of BAFF-treated cells, and 
tyrosine-phosphorylated proteins in immunoprecipitates were analyzed 
by Western blotting using antiphosphotyrosine antibody. The amounts 
of p85 and p110 in the immunoprecipitates were measured by Western 
blot analysis. (B) PI3K inhibition suppresses BAFF-induced Akt, GSK-3β, 
and FoxO1 phsophorylation. B cells were stimulated with BAFF in the 
absence or presence of LY294002, and protein phosphorylation was 
measured as described in Fig. 4. (C) Inhibition of PI3K reduces survival of 
BAFF-treated cells. B cells were cultured in medium alone (circles) or in 
the presence of BAFF (squares), LY294002 (triangles), or BAFF together 
with LY294002 (diamonds). The frequencies of viable B cells were deter-
mined by FACS analysis.JEM VOL. 203, October 30, 2006  2557
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division. However, the lack of BrdU incorporation in BAFF-
treated cells shows that BAFF does not induce DNA-replica-
tion, thus precluding cell division. Previous fi  ndings show 
persistent expression of Cdk inhibitor proteins p18 and p27 
in BAFF-treated cells (47). Therefore, it is likely that high 
expression of these and possibly other cell cycle inhibitors 
prevents the proliferation of BAFF-treated B cells in the ab-
sence of an antigenic signal.
BAFF-stimulated cells enter BCR-induced proliferation 
more readily than untreated cells. This result suggests that the 
accumulation of cell cycle–controlling proteins in response to 
BAFF prepares resting B cells for an immediate immune re-
sponse upon antigenic challenge. It is also attractive to specu-
late that, in response to BAFF, B cells might establish a storage 
pool of certain cell cycle–controlling mRNAs or proteins, 
which could be used for several rounds of cell division. Such 
a mechanism would help explain the astonishingly short rep-
lication time ( 7 h) of B cells at the height of the germinal 
center response (48, 49).
Akt activation requires two potentially independent 
  pathways. The PI3K-dependent pathway is shared both by 
BAFF-R and BCR. This feature of the pathway makes it 
particularly important in the regulation of B cell immunity 
and explains the poor survival of B cells in the absence of the 
p85 regulatory subunit of PI3K (50, 51). The pathway that 
involves PKCβ appears to be BAFF specifi  c. Thus, PKCβ 
defi  ciency impairs phosphorylation of Akt on activating ser-
ine 473 in response to BAFF but not BCR stimulation. The 
residual BAFF-induced Akt S473 phosphorylation, which 
we observe in the absence of PKCβ, indicates an ability of 
other kinases to partially adopt this role. This would be ex-
pected, as a plethora of kinases has previously been implicated 
in mediating Akt S473 phosphorylation (52).
Increased translocation of PKCβ to the plasma membrane 
and PKCβ association with Akt in response to BAFF suggest 
a direct involvement of PKCβ in BAFF signaling. Further-
more, PKCβ dependency of Akt phosphorylation at S473 
but not T308 agrees with in vitro data on Akt phosphoryla-
tion by PKCβ (38) and suggests a direct action of PKCβ on 
S473 of Akt upon BAFF stimulation.
Involvement of PKCβ in BAFF and BCR signaling pro-
vides a mechanistic explanation for the poor survival and 
Figure 6.  PKC𝗃 controls BAFF-induced Akt phosphorylation. 
(A) BAFF induces membrane translocation of PKCβ. B cells were stimu-
lated with BAFF followed by preparation of cytoplasmic and membrane 
protein extracts. PKCβ and Akt content in the extracts was measured by 
Western blotting. Fraction purity and protein loading was controlled by 
Western blotting using antibodies against Tubulin and Lyn. Numbers rep-
resent the fold change of PKCβ or Akt content in the membrane fractions 
normalized to the amount of Lyn. (B) BAFF induces PKCβ-Akt association. 
B cells were stimulated with BAFF, and protein extracts were treated with 
Akt antibody or control serum. The amounts of PKCβ or Akt in immuno-
precipitates (IP) or whole cell lysates (WCL) were measured by Western 
blot analysis. Amounts of PKCβ in Akt-IPs were quantifi  ed as fold change 
over the corresponding Akt signal. (C) Akt phosphorylation levels in B cell 
lysates derived from control and BAFF-treated PKCβ+/+ and PKCβ-defi  cient 
mice were measured and quantifi  ed as described in Fig. 4. n.d., no band 
detected by the quantifi  cation software (see Materials and methods). 
(D) B cells from PKCβ+/+ and PKCβ-defi  cient B cells were stimulated 
with BAFF or anti-IgM antibody as indicated. Akt phosphorylation in cell 
lysates was measured and quantifi  ed as described in C. Because there was 
no band detected by the quantifi  cation software at time 0 (n.d.), numbers 
in D represent the total quantifi  ed area of the phosphospecifi  c signal 
normalized to the total Akt content.2558  BAFF MEDIATES B CELL SURVIVAL AND GROWTH VIA AKT ACTIVATION | Patke et al.
  altered peripheral maturation of PKCβ-defi  cient B cells in 
vitro and in vivo. However, the relatively mild reduction of 
B cell numbers in the absence of PKCβ argues in favor of 
  additional PKCβ-independent signaling pathways initiated 
by BAFF-R and/or BCR. Signaling from both receptors in-
duces activation of NF-κB, albeit through distinct   mechanisms. 
Although PKCβ has an important function in canonical 
NF-κB activation upon BCR-triggering, BAFF-induced 
NF-κB2 processing is independent of PKCβ. Another PKC 
family member, PKCδ, also plays an important role in the 
regulation of B cell survival, but it promotes cell death rather 
than survival. The proapoptotic potential of PKCδ is con-
tained by BAFF, which prevents its accumulation in the nu-
cleus. This BAFF-dependent survival mechanism can also 
function in the absence of PKCβ.
BAFF-mediated B cell survival likely represents the 
collective outcome of several BAFF-induced signaling fea-
tures, including NF-κB activation, cytoplasmic retention 
of PKCδ, and Akt activation. It is thus conceivable that the 
loss of a single signaling branch can to some degree be 
compensated for. In this case, the loss of PKCβ would be 
expected to cause some damage to B cell survival, but it 
would be less severe than the complete abrogation of BAFF 
signaling. This could explain the more dramatic changes to 
the B cell compartment in BAFF- or BAFF-R–defi  cient 
mice than in PKCβ knockouts. Although PKCβ-defi  cient 
B cells were partially responsive to the survival action of 
BAFF, they appeared to be largely refractive to BAFF-me-
diated cell growth. This cellular process is closely associated 
with Akt- and mammalian target of rapamycin–dependent 
Figure 7.  BAFF-mediated cellular responses of PKC𝗃-defi  cient 
B cells are altered in vitro and in vivo. (A) B cells from PKCβ+/+ 
(squares) and PKCβ-defi  cient (triangles) B cells were cultured in medium 
alone (open symbols) or in the presence of 25 ng/ml (light gray symbols), 
100 ng/ml (dark gray symbols), or 250 ng/ml (closed symbols) of BAFF, 
and the frequencies of viable B cells were measured by FACS analysis. 
(B) The cell size of live BAFF-treated PKCβ+/+ (squares) and PKCβ-
 defi  cient (triangles) B cells was measured by FACS analysis of the forward 
scatter (FSC). Symbol shadings represent the same BAFF concentrations 
as in A. (C) BAFF-R expression on splenic B220-positive cells from 
PKCβ+/+ (continuous black line) and PKCβ-defi  cient (dashed black line) 
was measured by FACS. Gray lines (continuous and dashed) represent 
staining with an isotype control antibody. (D) Maturity of splenic B cells 
from PKCβ+/+ (left) and PKCβ-defi  cient (right) mice was assessed by 
expression of the surface markers IgD versus IgM (top) and CD21/35 ver-
sus IgM (bottom). Only live lymphocytes are shown, and the bottom panel 
is gated on B220-positve cells. Numbers in the top panels represent fre-
quencies of cells in the respective quadrants. Gates in the bottom panels 
denote B cell developmental stages T1 (IgMhi CD21lo), T2 (IgMhi CD21hi), 
and mature (IgMint CD21int).JEM VOL. 203, October 30, 2006  2559
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signaling pathways and represents an important distinction 
between growth factor–mediated cellular fi  tness on the one 
hand and mere cell survival on the other (19, 53). The lat-
ter can also be achieved through an altered ratio in the ex-
pression of pro- and antiapoptotic proteins, but, in this 
context, cells become progressively smaller (54). It appears 
that, perhaps in contrast to BAFF-induced NF-κB activa-
tion and cytoplasmic retention of PKCδ, which mediate B 
cell survival (55), PKCβ-dependent Akt activation prefer-
entially regulates the fi  tness facet of BAFF-mediated cellu-
lar responses.
Our fi  ndings may have practical implications. There is 
increasing evidence that BAFF plays an important role in the 
control of autoreactive B cells (8, 9, 13, 14, 56, 57). There-
fore, identifi  cation of Akt and PKCβ as components of BAFF 
signaling may suggest novel ways of pharmacological inter-
vention in B cell–mediated autoimmune disorders.
MATERIALS AND METHODS
Mice. Mice were housed in the Laboratory Animal Research Center at the 
Rockefeller University under specifi  c pathogen-free conditions. C57BL/6 
mice were used as a source of wild-type B cells. PKCβ-defi  cient mice on a 
C57BL/6 genetic background were used for analysis (39, 40). Mice were used 
at ages of 8–12 wk. Protocols were approved by the Institutional Animal 
Care and Use Committee at the Rockefeller University.
B cell purifi   cation and in vitro culture. Resting mature CD43−, 
CD62L+ B cells were isolated from spleen and lymph nodes by MACS 
(Miltenyi Biotec) according to the manufacturer’s instructions. The purity of 
mature B cells was routinely >95%. Cells were cultured for 12–16 h in 
RPMI 1640 medium supplemented with 10% FBS, 2 mM l-glutamine, 50 μM 
2-mercapto-ethanol, and 100 U/ml penicillin/streptomycin at 37°C in a 
CO2 incubator to reduce the background BAFF signaling caused by endog-
enous BAFF in vivo. This preincubation did not alter B cell size. After pre-
incubation, live cells were separated over a Ficoll gradient (Cedar Lanes), 
and their purity was assessed by trypan blue exclusion. Cells were stimulated 
in culture medium using 25 ng/ml BAFF (R&D Systems) or 1.3 μg/ml 
F(ab′)2 fragment goat anti–mouse IgM (Jackson ImmunoResearch Laboratories). 
LY294002 (Calbiochem) was used at a 10-μM concentration.
FACS analysis. Cells were analyzed on a fl  ow cytometer (FACSCalibur; 
Becton Dickinson) using CellQuest software (BD Biosciences). For mea-
surement of mitochondrial membrane potential, cells were used after 12–16 h 
of preincubation without BAFF (time point 0) or after 72 h of BAFF stimu-
lation. Cells were incubated in culture medium with or without BAFF 
and containing the potentiometric dye tetramethylrhodamine ethyl ester 
(TMRE; Invitrogen) at a 100-nM concentration. Carbonyl cyanide m-
  chlorophenyl hydrazone (Sigma-Aldrich) was added to control samples at a con-
centration of 50 μM as an uncoupler of the mitochondrial respiratory chain. 
After 30 min of incubation at 37°C in a CO2 incubator, cells were immedi-
ately analyzed by FACS. For BrdU incorporation, B cells were cultured in 
the presence of 10 μM BrdU, and fi  xed and stained using the FITC BrdU 
Flow Kit (BD Biosciences). For cell death analysis, an aliquot of  105 cells 
was removed from the B cell culture at various time points ranging from 
0 to 96 h. TO-PRO-3 (Invitrogen) was added at a concentration of 10 nM to 
distinguish live (TO-PRO-3−) and dead (TO-PRO-3+) cells in the culture 
samples. Upon TO-PRO-3 addition, cells were immediately analyzed by 
FACS. B cell surface marker expression was analyzed using antibodies against 
IgD, CD21/35, B220 (BD Biosciences), BAFF-R (R&D Systems), or 
a F(ab′)2 fragment of goat anti–mouse IgM (Jackson ImmunoResearch 
  Laboratories), as previously described (58).
Immunoblot analysis and immunoprecipitation. Cells were lysed in 
buff  er containing 150 mM NaCl, 20 mM Tris-HCl, pH 7.5, 1 mM EDTA, 
10% glycerol, 1% NP-40, 10 μM NaF, 2 mM Na3VO4, and protease inhibi-
tor cocktail (Sigma-Aldrich). Lysates were resolved by SDS-PAGE and trans-
ferred onto Immobilon-P membrane (Millipore) using standard procedures. 
Membranes were developed with the following antibodies against: pS6 
(S235/236), S6, peIF4E (S209), eIF4E, p4E-BP1 (S65), 4E-BP1, pAkt (S473), 
pAkt (T308), pGSK-3β (S9), GSK-3β, pFoxO1 (S256), FoxO1, pTSC2 
(T1462), pPTEN (S380), PTEN, and Erk (all obtained from Cell Signaling 
Technology); Pim-2, Akt, TSC2, and PKCβ (all obtained from Santa Cruz 
Biotechnology, Inc.); p85, p110δ, and pY (4G10; all obtained from Upstate 
Biotechnology); and tubulin (Sigma-Aldrich). Where applicable, membranes 
were fi  rst developed with phosphospecifi  c antibodies, and stripped and re-
probed with the respective control antibody. For Akt immunoprecipitation, 
lysates were precleared with goat-serum and protein G–Sepharose (GE 
Healthcare), followed by incubation with anti-Akt antibody overnight. Anti–
ferritin heavy chain antibody (Santa Cruz Biotechnology, Inc.) was used as 
a goat immunoglobulin control. Immune complexes were precipitated with 
protein G–Sepharose, washed fi  ve times in lysis buff  er, and eluted in SDS 
sample buff  er for SDS-PAGE. For p85 immunoprecipitation, lysates were 
precleared with rabbit immunoglobulin and protein A–Sepharose (GE 
Healthcare), followed by incubation with p85 antibody–agarose conjugate 
overnight. Immune complexes were washed and eluted as described earlier in 
this section. For analysis of NF-κB2 p100 processing and for the expression of 
cell cycle proteins, cells were lysed in a buff  er containing 350 mM NaCl, 20 mM 
Hepes/NaOH, pH 7.9, 1 mM MgCl2, 0.2 mM EDTA, 0.1 mM EGTA, 
1% NP-40, 20% glycerol, 10 μM NaF, 2 mM Na3VO4, and protease inhibi-
tor cocktail (Sigma-Aldrich). Lysates were analyzed by SDS-PAGE, and 
membranes were incubated with antibodies against NF-κB2 p52 (Upstate 
Figure 8.  (A) Unaltered BAFF-induced NF-B2/p100 processing in 
the absence of PKC. The presence of p100 and p52 was determined by 
Western blot analysis using an antibody against NF-κB2. Protein loading 
was controlled by Erk (p44/p42) expression. (B) Unaltered BAFF-induced 
cytoplasmic retention of PKCδ in the absence of PKCβ. Cytoplasmic and 
nuclear extracts were prepared from PKCβ+/+ and PKCβ-defi  cient B cells 
at time 0 and after 24 h of incubation in the absence (−) or presence (+) 
of BAFF. PKCδ expression was assessed by Western blotting. Fraction purity 
and protein loading were controlled by Western blotting using antibodies 
against Tublin and Lamin B. n.d., no band detected by the quantifi  cation 
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Biotechnology) or cyclin D2, cyclin E, Cdk4, and Mcm3 (all obtained 
from Santa Cruz Biotechnology, Inc.); Mcm2 and Rb (obtained from BD 
Biosciences); Ki67 (DakoCytomation); and Survivin (Chemicon). Signal 
quantifi  cation was done using NIH Image 1.63 software.
Lipid raft isolation. Lipid rafts were prepared as described previously (59). 
The purity of the preparation was assessed by the presence of Lyn and the 
lipid raft marker ganglioside GM1, which was detected using horseradish 
peroxidase–coupled cholera toxin B subunit (Sigma-Aldrich). Proteins were 
detected using antibodies against PKCβ, Akt, and PDK1 (all obtained from 
Santa Cruz Biotechnology, Inc.) and Lyn (a gift from C. Lowell, University 
of California, San Francisco, San Francisco, CA).
Subcellular fractionation. Fractionation of primary mouse B cells into 
cytoplasmic and nuclear extracts was performed as described previously 
(18). Lysates were analyzed for expression of PKCδ using an antibody from 
Santa Cruz Biotechnology, Inc. Fraction purity was assessed by Western 
blot analysis using tubulin as cytoplasmic and lamin B (Santa Cruz Biotech-
nology, Inc.) as nuclear markers, respectively. For preparation of cytoplas-
mic and membrane fractions, cells were disrupted by hypotonic lysis for 15 min 
on ice in a buff  er containing 10 mM Hepes, pH 7.4, 10 mM KCl, 1.5 mM 
MgCl2, 0.1 mM EDTA, 10 μM NaF, 2 mM Na3VO4, and protease inhibi-
tor cocktail (Sigma-Aldrich). Nuclei were removed by centrifugation at 
400 g for 10 min. The supernatant was then centrifuged at 95,000 g for 1 h 
in a SW55Ti rotor (Beckman Coulter). The supernatant was removed and 
saved as the cytoplasmic fraction. The pellet containing the membrane frac-
tion was resolved in SDS sample buff  er. Fraction purity was assessed by 
Western blot analysis using tubulin as cytoplasmic and Lyn as membrane 
markers, respectively.
Polyribosome purifi  cation and RNA isolation. Polyribosomes were 
purifi  ed essentially as described previously (60) from unstimulated cells and 
those that had been cultured in the presence of BAFF for 36 h. In brief, 
cells were incubated in culture medium containing 100 μg/ml cyclohexi-
mide (CHX; Sigma-Aldrich) for 15 min, washed three times in PBS con-
taining CHX, and lysed in 10 mM Hepes-KOH, pH 7.4, 150 mM KCl, 
5 mM MgCl2, 1% NP-40, 0.5 mM DTT, 100 μg/ml CHX, 200 U/ml 
RNAsin (Promega), 100 U/ml SUPERase (Ambion), and EDTA-free pro-
tease inhibitor cocktail (Roche). All chemicals were of molecular biology–
grade purity and nuclease free. Nuclei were removed from the extracts by 
centrifugation at 2,000 g for 10 min. An aliquot of the lysate was saved for 
preparation of total RNA. The remaining lysate was loaded onto a 20–50% 
wt/wt linear density sucrose gradient in 10 mM HEPES-KOH, pH 7.4, 
150 mM KCl, and 5 mM MgCl2. Gradients were centrifuged for 2 h at 
40,000 g at 4°C in a SW41 rotor (Beckman Coulter). Fractions of 0.7-ml 
volume were collected with continuous monitoring at 254 nm using an 
ISCO UA-6 UV detector. To identify polyribosome-containing fractions, 
the content of ribosomal S6 protein in the fractions after trichloroacetic 
acid precipitation was determined by Western blot. For RNA isolation, 
polysome-containing fractions were pooled, and RNA was isolated from 
total and polysomal samples using TRIzol LS (Invitrogen) according to the 
manufacturer’s protocol.
Gene expression analysis. Quality of RNA was confi  rmed before labeling 
by analyzing 20–50 ng of each sample using the RNA 6000 NanoAssay and 
a Bioanalyzer 2100 (Agilent Technologies). All samples had a 28S/18S ribo-
somal peak ratio of 1.8–2 and were considered suitable for labeling. 2 μg of 
total RNA was used for cDNA synthesis using an oligo(dT)-T7 primer and 
the SuperScript Double-Stranded cDNA Synthesis Kit (Invitrogen).  Synthesis, 
linear amplifi  cation, and labeling of cRNA were accomplished by transcrip-
tion in vitro using the MessageAmp aRNA Kit (Ambion) and biotinylated 
nucleotides (Enzo Diagnostics). 10 μg of labeled and fragmented cRNA 
were hybridized to the mouse genome MOE430 2.0 array (Aff  ymetrix), 
which interrogates  39,000 transcripts at 45°C for 16 h. Automated washing 
and staining were performed using the Fluidics Station 400 (Aff  ymetrix), 
  according to the manufacturer’s protocols. Finally, chips were scanned with 
a high numerical aperture and fl  ying objective lens in the scanner (GS3000; 
Aff  ymetrix). Raw expression data were analyzed using Microarray Analysis 
software (version 5.1; Aff  ymetrix). The complete datasets can be accessed 
at http://www.ncbi.nlm.nih.gov/geo under accession no. GSE5985. Data 
were normalized to a target intensity of 500 to account for diff  erences in 
global chip intensity. Genes, which were diff  erentially expressed between 
unstimulated and BAFF-treated cells, were initially identifi  ed using GCOS 
software. 377 transcripts showed a change of twofold or more (Table S2) and 
were selected for further analysis. Approximately three quarters of these genes 
were up-regulated upon BAFF stimulation, whereas one quarter was down-
regulated. For a biological interpretation of the diff  erentially regulated genes, 
the GoMiner gene ontology (GO) tool was used. GO is a genome project 
that describes gene products in terms of their associated biological processes, 
cellular components, and molecular functions (61). GO categories are orga-
nized in directed acyclic graphs, a kind of hierarchy in which one category 
can have more than one “parent.” GoMiner identifi  es GO categories that are 
over- or underrepresented in lists of genes of interest, such as diff  erentially 
expressed genes from a microarray experiment, and calculates statistical sig-
nifi  cance as the one-sided nominal unadjusted p-value from Fisher’s exact test 
(62). We report only those BAFF-induced biological processes in which the 
p-value was <0.001.
Protein identifi  cation. Gel-resolved proteins were digested with trypsin, 
batch purifi  ed on a reversed-phase microtip, and resulting peptide pools 
were individually analyzed by matrix-assisted laser desorption/ionization 
  refl  ectron time-of-fl  ight (MALDI-reTOF) mass spectrometry (MS; ultrafl  ex 
TOF/TOF; Bruker Daltronics Inc.) for peptide mass fi  ngerprinting (PMF), 
as previously described (63). Selected peptide ions (m/z) were taken to 
search a nonredundant (NR) protein database (3,245,378 entries on 28 January 
2006; National Center for Biotechnology Information) using the Peptide-
Search algorithm (developed by Matthias Mann, Max-Planck-Institute for 
Biochemistry, Martinsried, Germany; an updated version of this program is 
currently available as PepSea from Applied Biosystems/MDS SCIEX). 
A molecular mass range up to twice the apparent molecular weight (as esti-
mated from electrophoretic relative mobility) was covered, with a mass ac-
curacy restriction of <35 ppm and a maximum of one missed cleavage site 
allowed per peptide. To confi  rm PMF results with scores ≤40, mass spec-
trometric sequencing of selected peptides was done by MALDI-TOF/TOF 
(MS/MS) analysis on the same prepared samples using the ultrafl  ex instru-
ment in “LIFT” mode. Fragment ion spectra were taken to search the NR 
protein database using the Mascot MS/MS ion search program (version 
2.0.04 for Microsoft Windows; Matrix Science Ltd.) (64). Any tentative 
confi  rmation (Mascot score ≥30) of a PMF result thus obtained was verifi  ed 
by comparing the computer-generated fragment ion series of the predicted 
tryptic peptide with the experimental MS/MS data.
Online supplemental materials. Fig. S1 shows BAFF-induced Akt phos-
phorylation in the absence or presence of LY294002. Fig. S2 shows PTEN 
phosphorylation at serine 380, as well as total PTEN content in cell extracts 
prepared at various time points of BAFF stimulation. In Fig. S3, the distribu-
tion of PKCβ, Akt, and PDK1 into lipid rafts was analyzed before and after 
BAFF stimulation. Lipid raft–containing fractions are marked by the pres-
ence of Lyn and GM1. Fig. S4 shows BAFF-induced PKCβ-Akt association, 
which is not aff  ected by the presence of LY294002. Table S1 lists the gene 
IDs for the GO categories presented in Fig. 2 (B and C). Table S2 contains 
the complete list of Aff  ymetrix probe sets that showed a fold change of two 
or more in BAFF-stimulated versus unstimulated cells. Results are given both 
for RNA samples isolated from polysomes and analyzed in Fig. 2 (sheet 1 = 
polysome), as well as RNA samples derived from total cell lysates (sheet 2 = 
total). Online supplemental material is available at http://www.jem.org/
cgi/content/full/jem.20060990/DC1.
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